Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer

IMPORTANCE: The efficacy and safety profile of SARS-CoV-2 vaccines have been acquired from phase 3 studies; however, patients with cancer were not represented in these trials. Owing to the recommendation to prioritize high-risk populations for vaccination, further data are warranted. OBJECTIVE: To e...

Descripción completa

Detalles Bibliográficos
Autores principales: Goshen-Lago, Tal, Waldhorn, Ithai, Holland, Roy, Szwarcwort-Cohen, Moran, Reiner-Benaim, Anat, Shachor-Meyouhas, Yael, Hussein, Khetam, Fahoum, Liana, Baruch, Mali, Peer, Avivit, Reiter, Yoram, Almog, Ronit, Halberthal, Michael, Ben-Aharon, Irit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267843/
https://www.ncbi.nlm.nih.gov/pubmed/34236381
http://dx.doi.org/10.1001/jamaoncol.2021.2675

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267843/
https://www.ncbi.nlm.nih.gov/pubmed/34236381
http://dx.doi.org/10.1001/jamaoncol.2021.2675

Ejemplares similares